Further into the future, patients suffering from any type of virus could be cured with DRACO
Newly emerging flu viruses could soon be countered by a treatment that Draper Laboratory is developing that “traps” viruses before they can infect host cells.
Further into the future, patients suffering from any type of virus could be cured with DRACO, a drug also under development at Draper that is designed to rapidly recognize and eliminate cells infected by virtually any virus.
Both methods could help safeguard against bioterrorist attacks and naturally occurring pandemics in a manner that is unlikely to lead to treatment-resistant strains. Initial testing on the treatments, which each use tiny, non-toxic particles that can be injected, inhaled, or eaten, has shown them to be effective and safe against a multitude of strains of disease.
Nanotraps, which could be taken at the first sign of infection or exposure, is likely the first of the products ready for use, and is expected to begin clinical trials in two to five years, according to Jim Comolli, who leads the research on the effort at Draper.
Nanotraps, developed by a team of researchers from Draper, MIT, the University of Massachusetts Medical School, and the University of Santa Barbara, are nanoparticles that act as viral “traps” using specific molecules found naturally within the human body. A paper published in the March issue of Journal of Biological Chemistry detailed their findings.
The nanotraps look like the surface of a cell, with numerous carbohydrate molecules attached that closely resemble those targeted by flu viruses in the human respiratory system. These molecules, initially characterized in the Sasisekharan Lab at MIT, act as bait for the flu virus, which bind to the nanotrap instead of a host cell and are cleared away with mucus, preventing infection, Comolli said.
The research team has demonstrated in the laboratory that the nanotraps effectively countered multiple influenza strains able to infect humans and went on to show nanotraps protected mice infected with the flu. They have also developed additional particles geared toward other types of respiratory viruses.
Nanotraps, unlike most vaccines, are not strain specific and are designed to be effective against newly emerging strains of human-adapted influenza virus. Since nanotraps mimic a fundamental step in the viral life cycle – the binding of the virus to a host cell’s receptor – nanotraps may offer an opportunity to treat devastating infectious diseases without causing the development of treatment resistance, Comolli said.
The nanotrap molecule is composed mainly of compounds found naturally in the human body so it is likely to be safe as an inhalant, topical solution, or intravenous treatment and inexpensive to manufacture. With further development, nanotraps have the potential to treat a large range of infectious diseases because the attached carbohydrates can be tuned for other viruses such as HIV, Respiratory Syncytial Virus (RSV), and Herpes Simplex Virus (HSV), as well as bacteria and toxins.
The work was originally funded by the Defense Advanced Research Projects Agency (DARPA) to address emerging pandemics or bioweapons targeting US troops; Draper is continuing the research with the intent of applying it more broadly to the civilian community.
While nanotraps could be customized to treat a variety of viruses, another project underway at Draper, DRACO could do so with a single approach. DRACO is a unique therapeutic drug that should be effective against a very broad spectrum of viruses, just as existing antibiotics are effective against a broad range of bacterial infections. DRACO could be ready for human clinical trials in five to 10 years, according to Todd Rider, who leads the research at Draper.
DRACO (Double-stranded RNA Activated Caspase Oligomerizer) is designed to detect cells that have been virally infected and then eradicate only the infected cells, rapidly ending the infection. DRACO has proven effective in vivo against influenza and three hemorrhagic fever viruses, and in vitro against 15 different viruses – including common cold viruses, the H1N1 influenza strain, adenoviruses, a mouse polio virus, dengue fever, and stomach viruses, among others. It has also been tested and proven safe in both mice and 11 different human and animal cell types representing organs like the heart, lungs, liver, and kidney, among others.
DRACO is designed to be attracted to a specific type of RNA exclusive to viral infections – long double-stranded RNA, or dsRNA. Detecting this dsRNA in a human or animal cell indicates that that host cell has been taken over by a virus and is now in the process of creating more viruses. DRACO enters cells and attaches itself to any dsRNA. Once two or more DRACOs attach to the dsRNA, they interact with one another and activate a natural self-destruct switch inside the infected cell, terminating the infected cell and the virus that it was helping to reproduce.
The Latest on: Viral infections
via Google News
The Latest on: Viral infections
- I’ve had COVID and am constantly getting colds. Did COVID harm my immune system? Am I now at risk of other infectious diseases?on September 18, 2022 at 1:15 pm
Evidence is growing there are changes to your immune system that may put you at risk of other infectious diseases.
- Mumbai: City doctors witness spike in upper respiratory tract infectionson September 16, 2022 at 11:21 am
Doctors in Mumbai have once again noticed a spurt of viral infections over the last 10 days, especially those causing upper respiratory tract infections. This comes after the city witnessed heavy ...
- Persistent COVID Cases Seem to Encourage Viral Mutationson September 16, 2022 at 4:52 am
The majority of SARS-CoV-2 infections start to get better within several days, although infected people can shed virus and could infect others for anywhere | Coronavirus ...
- Repeated infections associated with increased risk of some neurodegenerative diseaseson September 15, 2022 at 1:23 pm
Infections treated with specialty hospital care in early- and mid-life are associated with an increased subsequent risk of Alzheimer’s (AD) and Parkinson’s diseases (PD), but not amyotrophic lateral ...
- Hospital-treated infections linked to increased risk of Alzheimer’s and Parkinson’son September 15, 2022 at 1:19 pm
A new study shows that hospital-treated infections, particularly during early and mid-life, increase the risk of developing Alzheimer’s disease and Parkinson’s disease later in life. However, the ...
- Infections that need hospital treatment may increase Alzheimer’s riskon September 15, 2022 at 11:00 am
An analysis of Swedish health records shows that people diagnosed with Alzheimer’s before age 60 are more likely to have been treated for an infection in hospital more than five years earlier ...
- COVID-19: A new, intranasal and anti-viral treatment could block infection transmissionon September 15, 2022 at 6:33 am
By the time people test positive for Covid-19, the SARS-CoV-2 virus has already taken up residence in their respiratory system. With each breath, people expel invisible viral particles into the air -- ...
- Healthy habits during monsoon that could help you avoid viral infectionson September 15, 2022 at 4:31 am
Contracting a virus is easier in the monsoon given that breeding grounds for viruses are in abundance. IndiaToday.in spoke to medical experts who advised on precautions one should take during the ...
- Research shows a complex relationship between vaping and SARS-CoV-2 infectionon September 14, 2022 at 5:46 pm
In a recent study posted to the bioRxiv* pre-print server, researchers at the University of California, Riverside investigated the effects of electronic cigarette (EC) use as a risk factor for severe ...
- SARS-CoV-2 viral infection is associated with an increased risk of Alzheimer’s diseaseon September 13, 2022 at 10:32 pm
Older people who were infected with COVID-19 show a substantially higher risk-;as much as 50% to 80% higher than a control group-;of developing Alzheimer's disease within a year, according to a study ...
via Bing News